No published contraindications exist for difelikefalin. Phase III clinical trials were conducted involving patients with comorbidities and polypharmacy, demonstrating promise for difelikefalin to have generalized applicability with low risk for drug-drug interactions. Difelikefalin does not interfere with liver enzymes.